IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
Metastatic HER2 Negative Breast Adenocarcinoma
M.D. Anderson Cancer Centerprotein_peptidePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 26/ 100
- Competitive Position
- 95/ 100
Competitive context
25 Active assets in the Metastatic HER2 Negative Breast Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 3 | BB |
Letrozole Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 4 | BB |
Inno-206 Virginia Commonwealth University | Phase 3 | BB |
TRASTUZUMAB Academic and Community Cancer Research United | Phase 3 | BB |
Carboplatin Genmab | Phase 3 | BB |
View all 50 →
Same molecule, other indications
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →